Click on a filter below to refine your search. Remove a filter to broaden your search.
Plasma with neutralizing antibody titer of at least 1:160 reduces mortality at 28 days versus standard care.
Associations were seen for working on the hospital unit, mood disturbances and sleep disturbances with depression and anxiety.
The risks were associated with COVID-19 severity.
SARS-CoV-2 targets plaque macrophages, and its entry is increased in cholesterol-loaded primary macrophages.
The prize panel said that their discovery ‘fundamentally changed our understanding of how mRNA interacts with our immune system.’
Differences were identified in circulating myeloid and lymphocyte populations, as well as exaggerated humoral responses against SARS-CoV-2.
No significant reduction was seen in the percent of patients with urgent care or emergency department visits or hospitalization.
Molnupiravir and nirmatrelvir-ritonavir combination therapy should be considered for patients within five days of symptom onset.
Patients with unrecognized need for COVID-19 therapy appear to have higher odds of readmission, regardless of race.
Those who survived COVID-19 had reduced mortality on days 181 to 365 and 366 to 730.